Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.71 |
| ▸ | LOX | P28300 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970998 | 0.88 | LOXL2 (0.64) | LOXL2LOXKCNH2AOC3LOXL3 | |
| SCHEMBL28641800 | 0.88 | LOXL2 (0.64) | LOXL2LOXKCNH2AOC3LOXL3 | |
| SCHEMBL19259776 | 0.84 | LOXL2 (0.71) | LOXL2LOXKCNH2AOC3LOXL3 | |
| SCHEMBL19274848 | 0.83 | LOXL2 (1.00) | LOXL2LOXKCNH2AOC3LOXL3 | |
| Hydrochloric Acid SCHEMBL19260005 | 0.82 | LOXL2 (1.00) | LOXL2LOXKCNH2AOC3LOXL3 | |
| Hydrochloric Acid SCHEMBL28661275 | 0.77 | LOXL2 (0.67) | LOXL2LOXKCNH2AOC3LOXL3 | |
| SCHEMBL19259880 | 0.75 | LOXL2 (0.40) | LOXL2 | |
| SCHEMBL29971595 | 0.74 | LOXL2 (0.62) | LOXL2LOXKCNH2AOC3LOXL3 | |
| SCHEMBL28657448 | 0.74 | LOXL2 (0.62) | LOXL2LOXKCNH2AOC3LOXL3 | |
| SCHEMBL19259857 | 0.72 | LOX (0.53) | LOXL2LOXKCNH2AOC3LOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |